AstraZeneca and CBMG's GPC3-Targeted Armored CAR-T Therapy C-CAR031 Granted IND Approval in China for Advanced Hepatocellular Carcinoma

Apr 26, 2024 16:23 CST Updated 16:23

AstraZeneca

Biopharmaceutical Manufacturer

AbelZeta Pharma

Clinical-stage biopharmaceutical company

Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Feel free to point out in the comments. This article is only an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved); this article does not constitute any investment advice.

Recently,The official website of CDE shows that Shanghai Sibiman Biotechnology Co., Ltd. ("Sibiman Biotech"), a wholly-owned subsidiary of Cellular Biomedicine Group,"Targeted GPC3 Armored Chimeric Antigen Receptor Autologous T-Cell Injection C-CAR031" Receives CDE Clinical Tacit Approval, for GPC3+ advanced/recurrent hepatocellular carcinoma.

Image Source:CDE Official Website

On December 7, 2023, Cellular Biomedicine Group (CBMG) announced a co-development agreement with AstraZeneca for C-CAR031. C-CAR031 is an armored autologous CAR-T therapy targeting glypican-3 (GPC3) for hepatocellular carcinoma (HCC). C-CAR031 is based on AstraZeneca's novel GPC3-targeted CAR-T (AZD5851), designed using AstraZeneca’s dominant-negative transforming growth factor-β receptor II (TGFβRII) armor discovery platform and manufactured in China by Cellular Biomedicine Group.

Under the terms of the agreement, CBMG and AstraZeneca will co-develop and commercialize C-CAR031 in China, with CBMG receiving an upfront payment. CBMG is also eligible to receive milestone payments and global development royalties when AstraZeneca independently develops, manufactures, and commercializes AZD5851 outside of China.

About CBMG Biotech

CBMG Biotech is a global biopharmaceutical company at the clinical stage, with innovation centers in Shanghai, China, and Maryland, USA. It focuses on developing innovative cell therapy products and is committed to combating malignant hematologic tumors, solid tumors, inflammation, and immune diseases through customized treatments that harness the body's own immune system. The company has GMP-compliant production facilities at each of its innovation centers to advance product development and early clinical research, with a pipeline covering CAR-T and TIL therapies.